Utility of a proliferation marker in distinguishing between benign naevocellular naevi and naevocellular naevus-like lesions with malignant properties.
In the present study we have investigated the utility of the proliferation marker MIB 1 in distinguishing between benign naevocellular naevi and naevocellular naevus-like lesions with malignant potential. Percentages of MIB 1 immunoreactivity in the intradermal portion of the lesions were determined. In benign congenital and acquired naevi, as well as in dysplastic naevi, there was no or only a slight intradermal melanocytic proliferation (0-2%), whereas vertical growth phase melanomas exhibited a substantial proliferative activity (11-48%). In five cases of naevus-lke lesions, which had all relapsed as unmistakable malignant melanomas (locally or metastatically) after primary surgery, there was also clear proliferative activity (9-67%). Our findings suggest that MIB 1 may be a useful tool in the routine histopathological examination of problematic naevocellular lesions.
Kanter
L
L
Department of Tumour Pathology, Karolinska Hospital, Stockholm, Sweden.
Blegen
H
H
Wejde
J
J
Lagerlöf
B
B
Larsson
O
O
D000911:Antibodies, Monoclonal; D002455:Cell Division; D003937:Diagnosis, Differential; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen; D008545:Melanoma / Q000473:pathology / Q000556:secondary; D009363:Neoplasm Proteins / Q000276:immunology*; D009364:Neoplasm Recurrence, Local; D009506:Nevus / Q000473:pathology*; D018330:Nevus, Intradermal / Q000737:chemistry / Q000473:pathology; D009687:Nuclear Proteins / Q000276:immunology*; D012878:Skin Neoplasms / Q000473:pathology*
D000911:Antibodies, Monoclonal; D019394:Ki-67 Antigen; D009363:Neoplasm Proteins; D009687:Nuclear Proteins